PRMT1

Across TCGA pan-cancer cohorts, PRMT1 RNA is linked to patient survival in 28 of 34 cancer types, making it the most broadly survival-associated PRMT1 data layer compared with 5 for mutation status and 6 for mass-spec protein.

The strongest signal is observed in mesothelioma (MESO), where higher PRMT1 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated PRMT1 expression acts as an unfavorable survival marker, although some lineages such as PCPG and CHOL show a favorable association.

MESO, LIHC, and ACC are the cancer types where PRMT1 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
MESO	OS	Median	All	0.419	0.650	<.001	114	view →
LIHC	OS	Median	All	0.609	0.784	<.001	77	view →
ACC	DFS	Median	All	0.423	0.737	<.001	77	view →
SKCM	DFS	Median	All	0.146	0.319	.002	39	view →
KIRP	OS	Quartile	All	0.864	0.988	.001	39	view →
SCLC	DFS	Median	III,IV	0.301	0.698	.002	35	view →
LGG	DFS	Median	All	0.674	0.803	<.001	34	view →
LUAD	OS	Median	All	0.765	0.855	.001	28	view →
KIRC	DFS	Quartile	IV	0.206	0.529	<.001	21	view →
UVM	OS	Tertile	All	0.564	0.917	.013	14	view →
PRAD	DFS	Quartile	All	0.707	0.886	.021	12	view →
HNSC	OS	Median	All	0.317	0.464	.014	11	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 28 lineages.

PRMT1–MESO (OS)

Open the MESO breakdown →